SEA-EPI-143 Distribution: General
Measles Mortality Reduction Regional Strategic Plan 2003-2005
WHO Project No: ICP IVD 100
World Health Organization Regional Office for South-East Asia New Delhi October 2003
© Word Health Organization (2003) This document is not a formal publication of the World Health Organization (WHO), and all rights are reserved by the Organization. The document may, however, be freely reviewed, abstracted, reproduced or translated, in part or in whole, but not for sale or for use in conjunction with commercial purposes. The views expressed in documents by named authors are solely the responsibility of those authors.
CONTENTS Page ABBREVIATIONS ..................................................................................................................V GLOSSARY ........................................................................................................................VI EXECUTIVE SUMMARY.........................................................................................................V 1. 2. 3. BACKGROUND AND OBJECTIVES ............................................................................. 1 BURDEN OF MEASLES IN THE REGION ..................................................................... 1 CURRENT STATUS OF IMPLEMENTATION OF MEASLES CONTROL STRATEGIES IN REGION........................................................................... 2 3.1 3.2 3.3 3.4 3.5 4. Routine immunization ....................................................................................... 2 Supplemental Immunization and Linkages with Polio Eradication and Vitamin A Delivery ..................................................................................... 3 Surveillance....................................................................................................... 3 Progress in 2002 and 2003 ................................................................................ 4 Summary........................................................................................................... 5
PLAN OF ACTION 2003-2005.................................................................................... 5 4.1 4.2 4.3 Specific Objectives ............................................................................................ 5 Key Milestones .................................................................................................. 6 Key Strategies .................................................................................................... 7
5.
ISSUES...................................................................................................................... 10 5.1 5.2 5.3 Rubella Control ............................................................................................... 10 Vitamin A........................................................................................................ 11 Immunization Safety, including Waste Disposal and Adverse Events following Immunization ........................................................... 11
6.
IMPLEMENTATION .................................................................................................. 11 6.1 6.2 6.3 Policy Development and Coordination ............................................................ 11 Mobilization of Human Resources ................................................................... 12 Regional Reporting System and Database......................................................... 12
Page iii
6.4 7.
Regional Laboratory Network .......................................................................... 13
CHALLENGES ........................................................................................................... 13 7.1 7.2 Ensuring Societal and Political Support............................................................. 13 Ensuring Adequate Supplies of Measles Vaccine of Assured Quality.................. 14
8. 9. 10.
MONITORING ......................................................................................................... 14 ADVOCACY, RESOURCE MOBILIZATION AND ROLE OF PARTNERS...................... 15 ESTIMATED ADDITIONAL RESOURCES REQUIREMENT .......................................... 15 Tables
1. 2. 3. 4. 5. 6. 7. 8.
Measles/Rubella Vaccine and Vitamin A Administration Schedules, South-East Asia Region 2002 ..................................................................................... 18 Current Status of Measles Control in the South-East Asian Region............................... 19 Age Distribution of Measles Cases Reported Through Routine Disease Surveillance (1999-2001).............................................................................. 20 Age Distribution of Measles Cases in Outbreaks ......................................................... 21 Measles Supplementary Immunization Campaigns Conducted in the South East Asia Region, 1997-2002*................................................................ 22 Estimated Vaccine and Injection Safety Wquipment Eequirement for Supplemental Immunization Activities. 2003-2005............................................... 23 Estimated Total Financial Resources Required to Achieve Measles Control Goals, 2003-2005......................................................................................... 23 Estimated Resources Requirement for Country Level Activities ................................... 24
Page iv
ABBREVIATIONS AFP GAVI CDC CIDA CRS DFID HIV ICC JICA MCV MMR MR NIDs OPV SIDA SEAR UNDP UNFP UNHCR UNICEF USAID VPD WHO – – – – – – – – – – – – – – – – – – – – – – – Acute Flaccid Paralysis Global Alliance for Vaccines and Immunization Centers for Disease Control and prevention (USA) Canadian International Development Agency Congenital Rubella Syndrome Department for International Development, United Kingdom Human Immunodeficiency Virus Interagency Coordinating Committee Japanese International Agency for Cooperation Measles containing vaccine Measles-Mumps-Rubella vaccine Measles-Rubella vaccine National Immunization Days Oral Polio Vaccine Swedish International Development Agency South-East Asia Region United Nations Development Programme United Nations Population Fund Office of the United Nations High Commissioner for Refugees United Nations Children’s Fund United States Agency for International Development Vaccine Preventable Disease World Health Organization
Page v
GLOSSARY Catch-up campaigns are one-time only events targeting multiple cohorts in which susceptible children have accumulated. The target age group depends on the measles susceptibility profile of the population. During a catch-up campaign all children in the target age range receive a supplementary dose of measles vaccine, regardless of prior disease or vaccination history. Follow-up campaigns are periodical events (E.g. every 3-5 years) to maintain low levels of susceptibility among preschool-aged children. The interval between campaigns depends on the routine immunization coverage and the existence of pockets of unprotected children. The target age group for immunization in these campaigns should include all children aged over nine months who were born after the previous mass immunization (e.g. catch-up campaign). GAVI: Global Alliance for Vaccines and Immunization. GAVI is a partnership dedicated to ensuring that all children have equal access to vaccines regardless of socio economic status. It also works to spur the development of new vaccines against major killers that primarily affect the world’s poorest people. It is founded on the principle that immunization is a human right and a key step towards overcoming poverty. Measles control: Reduction of measles morbidity and mortality in accordance with targets; continued immunization intervention measures are required to maintain the reduction. Measles elimination: The situation in large geographical area in which measles virus circulation has been interrupted, endemic transmission of measles cannot occur and sustained transmission does not occur following the occurrence of an imported case; continued immunization measures are required. Measles eradication: Interruption of measles transmission worldwide as a result of deliberate efforts; intervention methods may no longer be needed. Eradication represents the sum of successful elimination efforts in all countries. Routine immunization: Regular provision of immunization services to successive cohorts of infants through vaccination at fixed sites, door-to-door canvassing, outreach activities, or periodic pulse campaigns (one or more a year as appropriate). The activities usually involve the screening of vaccination records (selective immunization). Pulse campaigns: Periodic campaigns, usually conducted at the district level, targeting all children aged over nine months who were born after the last pulse vaccination. Supplementary immunization: Mass campaigns targeting all children in a defined age group, with the objective of reaching a high proportion of susceptible individuals. Each campaign is conducted over a wide geographical area (e.g. province or country) in order to achieve a rapid reduction in the number of susceptible children. It is not usual to conduct screening for vaccination status and prior disease history (i.e. the campaigns are usually nonselective)
Page vi
EXECUTIVE SUMMARY Since the introduction of the measles vaccine in the routine immunization programmes of the countries in the mid-1980s, the morbidity and mortality due to measles has been substantially reduced. However, measles remains the leading cause of childhood deaths and disability due to a vaccine preventable disease (VPD). According to global estimates of mortality, 202 000 measles deaths (29% of estimated global deaths) occurred in the countries of the Region in 2000(1). Immunization coverage levels of Member Countries in the Region indicate that there are many unvaccinated children in the SEA Region. In addition, the average seroconversion rate of 85% following a single dose of measles vaccine at nine months leaves a significant proportion of children susceptible(2). Accumulation of children who are either not immunized or do not develop immunity from one dose of vaccine in successive birth cohorts can result large measles outbreaks, even in countries where vaccination coverage is high. This situation warrants improving and accelerating measles control strategies in the Region. The overall goal of the regional strategic plan is to provide a framework for countries of the Region to contribute to the global goal of reducing the number of measles deaths by half by 2005 relative to 1999 estimates. The specific objectives are: (1) (2) To reduce the number of measles deaths by half by 2005 relative to 1999 estimates in polio- free countries of the Region; To achieve reliable monthly reporting of the number of measles cases and deaths, together with AFP, NT and other priority VPD, by all Member Countries by 2004; To achieve investigation of at least 20% of measles outbreaks by all Member countries in 2004 and 80% of outbreaks by 2005; To achieve and maintain 80% coverage with routine measles vaccination in at least 80% of districts in all Member Countries by 2005, and To provide a second opportunity for measles immunization to eligible children in Member Countries by 2005. Page v
(3) (4)
(5)
Regional Strategic Plan 2003-2005
Globally, two separate sets of strategies have been defined for measles mortality reduction and measles elimination(3). Countries in the South-East Asia Region have achieved varying levels of measles control. Bangladesh, India, Myanmar, Nepal and Timor-Leste, where measles mortality is high, should focus on reducing measles mortality. Other countries including Bhutan, DPR Korea, Indonesia, Maldives, Sri Lanka and Thailand have achieved low measles mortality levels, but experience periodic measles outbreaks. These countries, who have already achieved the standards set for mortality reduction, could strengthen their immunization strategies and surveillance standards towards elimination of measles. Large countries, including India and Indonesia should evaluate their large administrative areas separately and adapt specific strategies that are appropriate for those areas, either on mortality reduction or elimination. Improving routine immunization is the key strategy for sustainable measles mortality reduction and elimination. This plan endorses a second opportunity for measles immunization in addition to the first dose of measles vaccine at nine months of age(4). Immunization initiatives should be backed by an effective surveillance system to monitor disease epidemiology and vaccination coverage. Data generated should be used to assess the impact of immunization activities and adapt policies and strategies for targeted programme implementation. The existing polio surveillance system in the region provides a sensitive and responsive structure for high-quality disease surveillance and should be expanded to include measles and other vaccine preventable diseases. Based on the strengths of each national immunization programme, the second opportunity could be provided through supplementary immunization activities (SIAs) and/or through routine immunization services. It is also necessary to improve the management of measles cases through collaboration with initiatives which focus on reducing childhood mortality and morbidity. Moreover, ensuring immunization safety should be a priority. Opportunities to provide vitamin A, OPV and integrating rubella vaccination and surveillance could be considered where appropriate(5). Achieving polio eradication remains the top priority for the Region. Bangladesh, India, Indonesia, Myanmar and Nepal have a well-established polio eradication infrastructure, based on a network of surveillance officers supported by WHO. This network will most probably continue to operate for several years until such time global polio-free certification is achieved. These countries should take advantage of this infrastructure to support strengthening of routine immunization services and measles surveillance, including other VPDs as appropriate. Page vi
1.
BACKGROUND AND OBJECTIVES This document updates the regional plan of action for reducing measles mortality in the South-East Asia Region (SEAR), which was endorsed by the Technical Consultative Group for Vaccine Preventable Diseases in the SouthEast Asia Region (TCG) at its meeting in October 2001(6). It includes the recommendations of (i) the Joint WHO/UNICEF Inter-Regional Workshop on Measles Control and Maternal and Neonatal Tetanus Elimination Meeting held in February 2002, and (ii) the Partners’ Consultation on Measles Control in the Region held in February 2003. It is adapted from the WHO/UNICEF Global Strategic Plan for Measles Mortality Reduction and Regional Elimination 2001-2005, in which the primary goal is to reduce the number of measles deaths by half by 2005 relative to 1999 estimates(3). It provides a strategic framework for measles mortality reduction in the South-East Asia Region (SEAR) for the period 2003-2005 and the estimated external financial resources requirements. The global measles strategic plan was endorsed by the UN Special Session on Children in May 2002 and the World Health Assembly in May 2003.
2.
BURDEN OF MEASLES IN THE REGION Despite the declining trends in measles cases from a reported 440 000 in 1989 to 88 584 in 2002 corresponding to an increase in routine measles immunization coverage, measles remains a major cause of morbidity and mortality in the Region (Fig. 1). It is a major killer of children. Although data on reported measles cases and deaths are available in the Region, both are grossly under-reported. However, global estimates of measles deaths indicate that as many as 202 000 (29% of estimated global deaths) deaths occurred in the Region in 2000(1). The primary reason for this high burden is underutilization of measles vaccine in the Region and weak immunization services resulting in inadequate vaccination coverage. These deaths are unacceptable, because measles vaccine is safe, highly effective, and cost-effective(7, 8). Page 1
Regional Strategic Plan 2003-2005
3.
CURRENT STATUS OF IMPLEMENTATION OF MEASLES CONTROL STRATEGIES IN REGION Routine immunization All countries in the Region include a dose of measles containing vaccine in their routine immunization schedule. Sri Lanka provides a second dose as measles-rubella at three years of age and Thailand provides a second dose as measles-mumps-rubella at six years of age (Table 1). Routine vaccination of infants against measles since the mid 1980s has resulted in declining measles cases and deaths in the countries of the Region (Fig.1). However, measles vaccination coverage has remained stagnant around 80 percent in most countries. The decline in coverage in 2001 was mainly the result of a shift in India from administrative coverage to survey coverage as source of official coverage information. Figure 1: Reported Measles Cases and Coverage, SEAR, 1985-2002
3.1
Source: WHO/UNICEF Joint Reporting Form Page 2
Measles Mortality Reduction
The age distribution of measles cases varies within the Region (Table 2, 3 and 4). In Bhutan, Indonesia, Thailand, Sri Lanka and Maldives, the majority of cases reported occurred among children above five years, indicating relatively good measles control programmes. In India, Bangladesh and Myanmar, more than 50% of cases were reported in children less than five years of age, indicating insufficient routine measles immunization.
3.2
Supplemental Immunization and Linkages with Polio Eradication and Vitamin A Delivery In order to increase population immunity and reduce incidence of measles, most countries in the Region have conducted measles SIAs (Table 5). These have varied in geographical extent from national (DPR Korea in 1999 and Bhutan in 2000) to large sub-national (Bangladesh 2001, Maldives 2000 and Myanmar 2002) to urban areas/high risk areas (India 2001, Indonesia 2002 and Thailand 2000). The age groups targeted by these campaigns have also varied: 9-23 months, 9-35 months, 9-59 months, 6-59 months, 5-14 years, below 15 years, and 6 months to 18 years (Table 5). Several countries have used the opportunity provided by the national/sub-national immunization days for polio eradication to deliver other services, such as measles and TT vaccination and vitamin A administration. For example, Indonesia used the polio NIDs in 2002 to deliver measles vaccine in high risk villages. Bhutan delivered measles vaccine nationwide at the time of the second round of its SNIDs in 2000. Bangladesh, Nepal, DPR Korea and Indonesia used a round of the NIDs in 2002 to deliver vitamin A to targeted children.
3.3
Surveillance Achieving certification standard AFP surveillance is the overriding priority in the countries of the Region. Nonetheless, all countries in the Region have included measles in their communicable disease reporting systems, which routinely and passively reports numbers of cases, and deaths. Bhutan, Indonesia, Maldives, Sri Lanka and Thailand have established integrated surveillance systems that include measles surveillance. Page 3
Regional Strategic Plan 2003-2005
Bangladesh, India, Indonesia, Myanmar and Nepal use a WHO supported network of trained Surveillance Medical Officers (SMOs) to assist their governments in conducting AFP surveillance. In 2000, Myanmar started integrated AFP, measles and NT surveillance system, using the SMO network. In 2002, Bangladesh and Nepal developed guidelines and initiated training and implementation of an integrated AFP, measles and NT surveillance system. Nationally, India does not have a disease surveillance system in which disease information for measles and other vaccine preventable diseases (VPD) is used for immediate local action. However, a number of states in India have developed responsive, integrated disease surveillance systems. Number of disease surveillance efforts have been initiated, including a collaborative effort with the World Bank and WHO to develop a national plan for an integrated disease surveillance system that will include VPDs, communicable and non communicable diseases. A measles laboratory network has been established in the Region. Bangladesh, Bhutan, Indonesia, Maldives Myanmar, Nepal, Sri Lanka, and Thailand have national measles laboratories linked to epidemiological surveillance. Laboratory staff from all the countries, except DPR Korea and Timor-Leste has received training organized by WHO.
3.4
Progress in 2002 and 2003 In 2002, at the WHO/UNICEF inter-regional workshop, Member Countries were well-informed about measles control strategies and the need for integrated disease surveillance. Indonesia, Myanmar and Sri Lanka drafted national measles control plans and Myanmar conducted a mass measles campaign for 1/3 of the country. Bangladesh and Nepal started integrated disease surveillance. India has a plan of action to integrate AFP and measles surveillance in the polio-free states of Tamilnadu and Kerala. A measles laboratory network was established through training staff of the Member Countries in laboratory diagnosis to ensure laboratory support for epidemiological surveillance. In February 2003, a partner consultation on measles in the Region was conducted to review strategies and coordinate support to Member Countries.
Page 4
Measles Mortality Reduction
3.5
Summary In summary, the countries of the SEA Region are at varying stages of measles control (Table 2). Bhutan, DPR Korea, Maldives, Sri Lanka and Thailand have achieved low measles mortality. The other countries, especially those which have SMO-supported AFP surveillance, seem to have high measles mortality. The priority is to accelerate measles control in the Region, particularly in those countries with high mortality, building upon the experiences, momentum and infrastructure developed through polio eradication. To achieve this, development of partnerships and collaboration between Member Countries and international agencies will be crucial.
4.
PLAN OF ACTION 2003-2005 The overall goal of the regional strategic plan is to provide a framework for the countries of the Region to contribute to the global goal of reducing the number of measles deaths by half by 2005 relative to 1999 estimates.
4.1
Specific Objectives The specific objectives are: (1) (2) To reduce the number of measles deaths by half by 2005 relative to 1999 estimates in Polio-free countries of the Region; To achieve reliable monthly reporting of the number of measles cases and deaths, together with AFP, NT and other priority VPD, by all Member Countries by 2004; To achieve investigation of at least 20% of measles outbreaks by all Member Countries in 2004 and 80 % of outbreaks by 2005; To achieve and maintain 80% coverage with routine measles vaccination in at least 80% of districts in all Member Countries by 2005, and To provide a second opportunity for measles immunization to eligible children in member Countries by 2005.
(3) (4)
(5)
Page 5
Regional Strategic Plan 2003-2005
4.2
Key Milestones By 2003 Ø Ø All countries of the Region would have a 3-5 year national plan of action for measles mortality reduction. Regional guidelines for accelerated VPD surveillance and supplementary immunization activities (SIAs) would be developed and disseminated. All countries, including polio-free states in India, would accelerate measles surveillance and begin to investigate measles outbreaks. A Measles Laboratory Network would be established with at least one measles laboratory in every Member Country. All countries in the Region would have strategies in place to increase access to routine immunization. Myanmar and Sri Lanka would implement SIAs as planned. All countries would have accelerated measles surveillance including active surveillance, outbreak investigation, laboratory confirmation and weekly or monthly reporting to the national level and to the Regional office. Integrated AFP, measles and NT surveillance would be extended to other states in India. Measles and rubella surveillance reviews would be conducted in priority countries. Myanmar and Sri Lanka would complete SIAs as planned. Indonesia, Maldives, Nepal and Timor-Leste would conduct mass campaigns as appropriate. All countries in the Region would achieve key measles surveillance performance indicators. All countries in the Region would have at least 80% coverage of measles vaccine in at least 80% of their districts. Bangladesh, India and Nepal conduct would SIAs as appropriate. A revised long-term plan would be developed for control of measles, rubella and congenital rubella syndrome (CRS) in the Region.
Ø Ø Ø Ø By 2004 Ø
Ø Ø
By 2005 Ø Ø Ø Ø
Page 6
Measles Mortality Reduction
4.3
Key Strategies The key regional strategies to achieve the goal of measles mortality reduction are: Ø Ø Achieving high routine measles vaccination coverage of infants at nine months of age or shortly thereafter; Providing a second opportunity for measles immunization to appropriate age groups of children through either a second routine dose of measles containing vaccine (MCV) or through supplemental immunization activities; Conducting effective measles surveillance that provides information at a minimum; about number of cases and deaths by month, age and vaccination status of cases and deaths, conducts outbreak investigation and monitors routine vaccination coverage, and Improving management of measles cases, including vitamin A supplementation and adequate treatment of cases.
Ø
Ø
These strategies are described in detail in the Global Strategic Plan for Sustainable Measles Mortality Reduction and Regional Elimination 20012005, a plan that was jointly developed by WHO and UNICEF(3). The plan categorizes the strategies into “Mortality Reduction” and “Elimination” according to measles control targets. In both categories, the strategies are similar, except for the following in the “Elimination” category: Ø Ø Higher level of achievement set for routine immunization and Case-based measles surveillance
Since the regional goal is sustainable measles mortality reduction, it is necessary for all countries in the Region to adopt at least the mortality reduction target and develop a multi-year plan of action with emphasis on achieving and sustaining high population immunity, improving the quality of measles surveillance to identify changes in measles epidemiology and forecast outbreaks, and evaluating programmes to decide further intervention. The plan of action should include an appropriate section on ensuring and monitoring immunization safety, as well as adverse events following immunization (AEFI).The following WHO publications, available in the website www.who.int/vaccines-documents provide the necessary technical guidance.
Page 7
Regional Strategic Plan 2003-2005
(1) (2) (3) (4)
Measles Mortality Reduction and Regional Elimination Strategic Plan 2001-2005 (WHO/V&B/01.13) Module on best (WHO/V&B/01.43) practices for measles surveillance
Manual for the laboratory diagnosis of measles virus infection, (WHO/V&B/00.16) WHO guidelines for epidemic preparedness and response to measles outbreaks (WHO/CDS/CSR/ISR/99.1)
It is recognized that Member Countries of the Region are at varying stages of measles control, with some at a more advanced stage than others. The countries that have already achieved the standards set for mortality reduction could strengthen their immunization strategies and surveillance standards towards elimination of measles. Bhutan, DPR Korea, Indonesia, Maldives, Sri Lanka and Thailand have achieved low measles mortality levels, but continue to experience periodic measles outbreaks. These countries should implement strategies to raise and/or maintain evaluated routine measles immunization coverage of infants to at least 80 percent in all districts. An immediate priority is to strengthen surveillance and fully investigate measles outbreaks. Proper case management with administration of vitamin A should be an integral feature of outbreak investigation(9). Depending on the strength of the national surveillance system, these countries could decide to conduct case-based measles surveillance. These countries should work towards providing a second opportunity for measles immunization targeting populations susceptible to measles. Sri Lanka and Thailand have already included a second dose of measles containing vaccine in their immunization schedule. Other countries could consider a two-dose vaccination schedule, provided that the system in the country has the capability to maintain high coverage for both doses and there is a system for following up of defaulters(4). Since at the time of introducing a second dose to a national immunization schedule, there are children who are older than the age for second dose, SIAs are recommended to be conducted as an early step in a measles control plan to catch up the children in susceptible age groups. Before a decision is taken to conduct a supplementary vaccination campaign, countries should refer to the global strategic plan for details of this approach and aspects that should be considered. Campaigns conducted prior to the introduction of a second routine dose need to be
Page 8
Measles Mortality Reduction
national in scope and target a wide age group(3), usually 9 month to 15 year olds. However, the exact age group to be targeted should be determined on the basis of analysis of measles data(4). Bangladesh, India, Myanmar and Nepal continue to have a high burden of measles cases and deaths. The measles burden in Timor-Leste is not well known. The priorities in these countries are to raise and sustain routine immunization coverage, conduct effective surveillance and offer a second opportunity for measles immunization to age groups at highest risk of measles mortality. These countries should track and investigate outbreaks to get a better understanding of measles epidemiology(10). Case management and vitamin A administration should be an integral feature of outbreak investigation(9). A second routine dose of measles vaccine is not recommended at the moment. However, SIAs may be required and in order for these to have optimal impact, they should be of sufficient geographical extent and target the appropriate age groups and susceptible groups as determined by the measles epidemiology. Although there is no fixed target age group, initial campaigns in countries with high mortality can target nine months to five year olds, with periodic follow-up campaigns targeting all children aged over nine months who were born after the last campaign and any other susceptible age groups. However, experience in Africa and the Americas has shown that targeting a wider age range, (e. g nine months to 15 years) often results in a more immediate reduction in measles mortality. Bangladesh, India, Indonesia, Myanmar and Nepal have a wellestablished polio eradication infrastructure, based on a network of surveillance officers supported by WHO, which will most probably continue to operate for several years until such time as global polio-free certification is achieved (Fig 2). These countries should take advantage of this infrastructure to support strengthening of routine immunization services and measles surveillance, including other VPDs as appropriate. Depending on the capability of the system, countries may consider implementing case-based measles surveillance. Large countries in the Region, such as India and Indonesia, should evaluate their large administrative areas separately and adapt the implementation of the strategies as appropriate.
Page 9
Regional Strategic Plan 2003-2005
Figure 2: Polio eradication infrastructure, SEAR, 2003:Building on AFP surveillance to support measles and other VPD surveillance
BGL: 32 SMOs, 6 DC IND: 258 SMOs, 7 RCS, 13 SRCs
NEP: 17 SMOs INO: 38 SMOs MMR: 17 SMOs
As of 21 Apr. 2003
IVD/SEARO
5. 5.1
ISSUES Rubella Control Sri Lanka and Thailand have included combined measles-rubella vaccine in the routine immunization programmes. Some of the other countries are exploring the use of combined measles-rubella and measles-mumps-rubella vaccine in their routine immunization programmes. WHO recommends that the priority of any congenital rubella syndrome (CRS) prevention programme is the protection of women of child bearing age. If child rubella immunization is implemented, rubella immunization of adult women should be introduced at the same time or earlier. Rubella vaccine should be added to the infant immunization schedule only if coverage >80% can be sustained on a longterm basis. Inadequately implemented childhood rubella immunization programme runs the risk of altering rubella transmission dynamics by shifting the average age of infection to women in child bearing age and then potentially increasing the incidence of CRS cases(5,11).
Page 10
Measles Mortality Reduction
5.2
Vitamin A Several studies have shown that the administration of vitamin A during a measles episode reduces severity of measles and measles case fatality ratios(12, 13) . It is vital that all measles patients receive vitamin A as part of the treatment irrespective of whether it has been previously administered and whether immunization has been given. In order to promote overall improvements in child health, measles vaccination should be used as an opportunity to administer vitamin A prophylaxis in areas where vitamin A deficiency is prevalent. All children with measles should be treated with two doses of vitamin A whenever they reach health services, with special attention to provide vitamin A during measles outbreak investigations. Measles SIAs can be used as an opportunity to provide vitamin A supplementation for children in appropriate age groups(3).
5.3
Immunization Safety, including Waste Disposal and Adverse Events following Immunization The administration of millions of doses of measles vaccine during measles SIAs necessitates careful planning and training at all levels, availability of sufficient injection safety equipment and safe disposal of used syringes and needles(14,15). Tools are available to assess immunization safety and develop and implement safety plans for routine immunization and mass campaigns(16). Strengthening the reporting, investigation and responding to adverse events following immunization is important, since these events can cause disability and death and public reluctance to immunization strategies. When measles SIAs are conducted, immunization safety and adverse events following immunization should be promptly monitored. WHO would monitor measles plans of action of the countries to ensure that this component is adequately addressed.
6. 6.1
IMPLEMENTATION Policy Development and Coordination Regional policy and strategy development and the implementation and monitoring of the programme will be coordinated at the regional level with Page 11
Regional Strategic Plan 2003-2005
national governments and partners through the Regional Partners Consultation, the SEAR EPI Managers Meeting, and the SEAR Technical Consultative Group (TCG). At the country level, WHO will promote the national Inter-Agency Coordinating Committee (ICC) as the principal coordinating mechanism. WHO/SEARO will coordinate the development of regional guidelines and tools, and the development and institutionalization of a regional reporting system and a regional laboratory network. For both routine immunization and supplementary campaigns, countries need to coordinate with UNICEF to ensure adequate supply of measles vaccine.
6.2
Mobilization of Human Resources In consultation with donors and other partners, polio-funded staff in Member Countries will be increasingly used to support implementation of the plan. In polio-free countries, this could be done without compromising AFP surveillance quality. In India, staff in polio-free provinces may be able to spend as much as 25 percent of their time on non-polio EPI and VPD surveillance activities. Efforts will be made to broaden the resource base to insure that polio-funded staff can expand their responsibilities. Additional staff requirements for the measles professional officer and a full-time One full time national professional with one required for Bangladesh, India, Indonesia, funding will be sought for them. regional office are: a full-time measles laboratory coordinator. programme assistant will also be Myanmar and Nepal. External
6.3
Regional Reporting System and Database A regional reporting system and database are currently being developed to monitor the changing measles epidemiology within the Region, to prioritize the resource needs, and make informed decisions about establishing a regional elimination goal in 2005. This is being developed based on the experiences of the polio surveillance system and will focus on integrated reporting of acute flaccid paralysis (AFP), measles and neonatal tetanus (NT). For those countries with electronic reporting systems, compatibility with the regional reporting system will be assessed. For countries without electronic reporting systems, an electronic system will be provided with support for training and implementation. All Member Countries are encouraged to have a
Page 12
Measles Mortality Reduction
national level database similar to the AFP-IFA database to enter and analyze data as well as feed it forward to SEARO. Member Countries will be expected to report monthly aggregate data on the following core variables. Ø Ø Ø Ø Ø Ø Number of cases by age Number of cases by districts Number of cases by immunization status Number of cases by gender Number of cases by outcome Number and percentage of specimens serologically confirmed for measles and rubella
In outbreak situation case base data is preferred for the above core variables but aggregate data is acceptable. The SEAR weekly polio bulletin will be redesigned as a VPD reporting bulletin, once the reporting system has been established.
6.4
Regional Laboratory Network A regional measles laboratory network is being established to provide laboratory support to the programme in the countries. This will be based on the experiences gained in the polio laboratory network. However, it is envisaged that the measles network will require more national laboratories than the polio network. The laboratories will have adequately trained personnel, appropriate equipment and reagents. All laboratories will do serological tests to confirm or discard suspected measles and rubella cases. All countries will have access to a laboratory able to isolate measles virus from appropriately collected urine or nasopharyngeal specimens. Additionally, regional reference laboratories will be established to support national laboratories. Whenever necessary, virus isolates will be sent to a global reference laboratory for genetic characterization.
7. 7.1
CHALLENGES Ensuring Societal and Political Support The Inter-agency Coordinating Committees (ICC) in the countries should ensure that communication, social mobilization and advocacy are Page 13
Regional Strategic Plan 2003-2005
components of the national measles plan of action. Indicators will be developed for this purpose and monitored by WHO at the regional level. National authorities need to be informed and convinced of the value of measles control activities to ensure that measles activities are given due priority. Such activities should be seen as worthwhile investment in the future. At the community level, families and community leaders should be encouraged to accept and practise the recommended measles control strategies, such as participation in routine immunization or SIAs. Advocacy to build the requisite high-level support for the implementation of measles mortality reduction plans and for the further development of routine immunization services is a priority. In particular, efforts will be made to ensure that sufficient resources are available to countries where measles mortality is high. Countries in receipt of GAVI funds should utilize these for strengthening immunization delivery systems.
7.2
Ensuring Adequate Supplies of Measles Vaccine of Assured Quality A 3-5 year forecast of vaccine needs and a multi-year funding proposal will be prepared to secure adequate vaccine supply for countries in the Region for both routine and supplemental immunization. In this connection, it is vital to increase the effectiveness and timeliness of forecasting of both demand and production capacity at national levels(3). On the basis of the current epidemiology and maturity of the programme in the countries, activities are suggested for discussion and planning with Member Countries (table 2). The timing of these activities, the extent and age groups to be targeted would depend on country preparedness and would be subjected to availability of funds and vaccines. The estimated amount of vaccines and injection safety equipment required for countries to conduct supplementary immunization activities is appended (Table 6).
8.
MONITORING The following key indicators have been identified to monitor the implementation of measles control strategies at national and regional levels. Ø Number of countries with measles plan of action
Page 14
Measles Mortality Reduction
Ø Ø Ø Ø Ø Ø Ø Ø
Annual number of reported measles cases and deaths Percentage of outbreaks investigated Percentage of known outbreaks confirmed serologically Measles immunization coverage – national level Percentage of districts with routine measles coverage <50%, 5079%, 80-94%, 95%+ Coverage of mass campaigns- national level Percentage of districts with mass campaign coverage level <80%; 80-94% and >=95% Completeness and timeliness of monthly surveillance reports.
In addition, countries implementing elimination strategies could monitor the progress using the specific indicators mentioned for elimination in Module on best practices for measles surveillance (WHO/V&B/01.43)
9.
ADVOCACY, RESOURCE MOBILIZATION AND ROLE OF PARTNERS National governments, with technical and financial support from WHO, UNICEF and the Centers for Disease Control (CDC), Atlanta, will take the lead in the implementation and monitoring of the recommended strategies. In 2003, a strategic plan for advocacy and sustainable resource mobilization will be developed in consultation with Member Countries and partners. Every effort will be made to extend the partnership to national academic institutions contributing to the development of strategies and new technologies and other bodies, such as GAVI, CVP, UNDP, USAID, CIDA, DFID, DANIDA, European Commission, KfW, JICA, Government of the Netherlands, SIDA, American Red Cross, IRC and red cross/crescent organizations in the region.
10.
ESTIMATED ADDITIONAL RESOURCES REQUIREMENT Key activities for regional plan of action have been identified based on the available country plans for measles control and the minimum requirement of mortality reduction in all countries. The estimates were calculated on the basis of additional activities appropriate for countries. The budget includes the cost Page 15
Regional Strategic Plan 2003-2005
estimates for surveillance including laboratory support, mass measles campaigns, and regional coordination. Funds required for routine immunization have not been included. Estimated cost for laboratory network is based on joint assessments made by WHO staff/consultants with country focal points. The final requirement for resources and their allocation to national and regional levels will be based on more detailed 3-5 year country plans of action. Table 7 summarizes the additional resource requirement for the period 2003-2005. Table 8 provides a detailed country wise requirement of estimated additional resources for the period 2003-2005. These figures provide an indicative target for resource mobilization. Exact figures would change yearly depending upon the results of the resource mobilization efforts and progress with the implementation of the Regional Plan of Action.
Page 16
Measles Mortality Reduction
References (1) (2) (3) (4) (5) (6) (7) (8) The World Health Report 2001. World Health Organization, Geneva 2000. Measles control in the 1990s: principles for the next decade. Geneva, World Health Organization. WHO/EPI/GEN/90.2 (available at WHO web). World Health Organization, United Nations Children’s Fund. Measles, Mortality reduction and regional elimination. Strategic Plan 2001-2005. WHO/V&B/01.13. World Health Organization. Strategies for reducing global measles mortality, WER 2000;50:411-416. Report of the meeting on preventing congenital rubella syndrome, immunization strategies, surveillance needs, WHO/V&B/00.10. Building on Polio: Improving access and strengthening EPI, Report of the Eighth meeting of the Technical Consultative Group on vaccine preventable diseases in SEAR, SEA-EPI-140. Felicity T Cutts The immunological basis for immunization Module 7: measles, WHO/EPI/gen/93.17. Edmundus WJ et al. The cost-effectiveness of Haemophillus Influenza type B (hib) and measles vaccination in developing countries: London, department of economics, City university and PHSL communicable disease surveillance centre. WHO guidelines for epidemic preparedness and response to measles outbreaks (WHO/CDS/CSR/ISR/99.1). Module on best practices for measles surveillance (WHO/V&B/01.43). Preventing congenital rubella syndrome. Weekly epidemiological report 2000;75(36):290-295. Beaton GH et al. Vitamin A supplementation and child morbidity and mortality in developing countries. Food and nutrition bulletin, 1994:15 (4) Dollimore N et al. Measles incidence case fatality and delayed mortality in children with or without vitamin A supplementation in rural Ghana. American journal of Epidemiology1997 146(8):646-654. Safety of injections: WHO-UNICEF-UNFPA joint statement on the use of auto disable syringes in immunization services (WHO/V7B/99.25). WHO-UNICEF policy for statement for mass immunization campaigns (WHO/EPI/LHIS/97.04). World Health Organization and SIGN. Injection safety: Toolbox to assess and evaluate injection practices sign.
(9) (10) (11) (12) (13) (14) (15) (16)
Page 17
Regional Strategic Plan 2003-2005
Table 1: Measles/Rubella Vaccine and Vitamin A Administration Schedules, South-East Asia Region 2002* Country Bangladesh Measles, measles-rubella, measles/mumps/rubella vaccine One dose at nine months (M-V) Vitamin A (during routine EPI) Under one year, usually with measles vaccine Six months x 3, school children every six months Twice to children 6-59 months, six month interval Nine months then every 6 months until three years 6-11 months, 12-59 months Twice yearly from 6 months – 5 years NA Twice yearly ages 6-60 months
Bhutan
One dose at nine months (M-V)
DPR Korea
One dose at nine months (M-V)
India
One dose at nine months (M-V)
Indonesia Maldives
One dose at 9-11 months (M-V) One dose at nine months (M-V)
Myanmar Nepal
One dose at nine months (M-V) One dose at nine months (M-V) (up to 36 months if recommended dose missed) One dose at nine months (M-V) One MR at three years Two doses MMR (or MR if MMR is not available): 9-12 months and six years
Sri Lanka
At 9 months, 18 months and 5 years NA
Thailand
* Source: WHO vaccine-preventable disease monitoring system, 2001 global summary
Page 18
Measles Mortality Reduction
Table 2: Current status of measles control in the South-East Asian Region Reported incidence for 100,000 pop 2002. 2.43 1.23 0.00 4.93 6.67 299.76 1.51 27.43 0.74 16.47 Reported measles vaccination coverage 2002(1) Polio eradication(5) Measles surveillance status Integrated with AFP Yes Yes Yes No Yes Yes Yes Yes Yes Yes No
Country
Reported Measles cases 2002(1)
Measles cases below 5 years %(2)
Under 5 mortality rate (3)
Non Last polio Polio Method case AFP rate 2002 2000 Aug 1986 1996 2003 Sep 1995 Oct 1994 2000 Feb 2000 Nov 1993 Nov 1997 Apr 2.70 0.38 1.11 1.87 1.29 3.28 1.90 1.98 1.41 2.00 Active Passive Passive Passive Passive Passive Passive Active Active Passive Passive
Data
Bangladesh Bhutan DPR Korea India Indonesia Maldives Myanmar Nepal Sri Lanka Thailand Timor-Leste SEAR
3 494 27 0 51 780 14 492 926 736 6749 139 10 241
72.3(R) 28(R) ND 74.5(O)* 36.5(R ) 6.9(O)** 59.1(R) ND 13(O) 32.8(R)
92 80 50 86 49 47 133 98 23 26
65 (S) 78 (A) 97 (A) 67 (S) 44 (S) 99 (A) 75 (A) 71 (S) 99 (S) 94 (S)
Case based Case based Aggregate Aggregate Aggregate Case based Aggregate Case based Case based Aggregate Aggregate
88 584
5.57
68
(1) (2)
(3) (4) (5)
WHO/UNICEF joint reporting forms from the countries, (S) survey coverage, (A) administrative coverage EPI/TCG forms for all countries except India and Maldives. outbreak investigations, (R) Routine reporting system, (O) Outbreak Investigation, (ND) No data * Indian Journal of Paediatrics Vol. 69 Jan 2002, ** outbreak investigation 2002 World population prospectus: The 2000 revision WHO vaccine preventable disease monitoring system 2001 global summery, Weekly polio bulletin SEAR
Page 19
Regional Strategic Plan 2003-2005
Table 3: Age distribution of measles cases reported through routine disease surveillance (1999-2001) Total No. of measle s cases Age distribution (Percentage of cases in each age group) <9 M 2.4 14.9 14.2 18.6 6.7 9-11 M 7.3 4.5 7.1 1-4 Y 46.3 37.3 44.4 39.5 21.1 5-9 Y 29.3 21.9 20.7 41.9 72.2 100 8.6 11.3 0.3 0.4 0.9 6.4 4.3 4.7 19.1 15.5 10.8 5.4 11.2 7.0 2.6 2.8 2.4 26.8 25.2 27.6 32.3 51.2 4.9 6.3 10.2 25.4 23.3 22.0 42.8 36.5 27 32,1 19 16.3 6.3 21.5 19 22.1 33.9 15 22.3 22.6 7.8 14.7 15.8 7.1 13.6 16.1 22.7 18.2 32.3 1.1 52.4 54.5 28.3 20.3 26.1 5.0 8.7 30.7 5.7 7.9 6.5 0 10-14 Y 14.6 14.9 7.7 1.8 15-19 Y 20-24 Y 0 1.5 1.8 2.4 > 25 Y
Country
Year
1999 Bangladesh 2000 2001 1999 Bhutan 2000 2001 1999 Indonesia 2001 1999 Myanmar 2000 2001 1999 Sri Lanka 2000 2001 1999 Thailand 2000 2001
46 67 149 86 418 756 10 805 3 715 1 196 712 1 503 1 635 3 945 127 3 312 4 074 7 319
Source: Table 3 of EPI/TCG form from 1999-2001 received from Member Countries
Page 20
Measles Mortality Reduction
Table 4: Age distribution of measles cases in outbreaks Age distribution (Percentage in each age group) <9 M 9-11 M >25 Y
Country
Year
Total No. of Cases
No. of outbreaks
1-4 Y
5-9 Y
10-14Y
15-19 Y
20-24 Y
Bhutan India Indonesi a
1997 1999a 2001b 2000c 283 183 50 915 563 549 1629 60 6 392 58 781
1 1 4 1 1 5 5 11 1 1 3 8 4.8 6.7 0.8 0 5 41.4 1 2.2
3 7.8 0.5
20 66.7 29
12 24.8 31.7
18
47 0.7
35 36
1.6 64 37.9 0 5.3 1
0
0
Maldives 2002d 1999e Myanma r 2000e 2001e Nepal Sri Lanka 2000f 2000g 2000e Thailand 2001e 4.9 46.7 20.2 17.2 1.2 0 0.9 2.0 0 16.6 6.4 4.9 47.4 16.9 47.2 13 2.7 1.7 5.3 0 14.6 31.6 39.7 40.1 33 16.3 3 26.1 16 14.8 7.2 37 16 22 10.5 0 3.0 0
17 54.8 8
a. Indian Journal of Paediatrics, Jan 02 b. EPI/TCG form c. EPI/TCG form d. Outbreak 2002 e. EPI/TCG form f. Outbreak 2000 g. EPI/TCG form
Page 21
Regional Strategic Plan 2003-2005
Table 5: Measles supplementary immunization campaigns conducted in the South East Asia Region, 1997-2002* Country Bangladesh Year 1995 1999 2001 Bhutan 1995 2000 1999 2000 Campaign Sub national -130 sub districts Sub national - 52 High Risk areas Sub national High risk unions National catch up campaign 20 districts National Catch up campaign Urban measles campaign in four states Urban measles campaigns High risk areas School catch up campaign in two provinces Multi-antigen campaign with SNIDs in five provinces Sub-national Catch up with OPV High risk areas Sub national Mop up campaign 82 urban townships 1/3 of the country Catch up campaign in 74 townships in two divisions Three districts Outbreak response Target age group 9-23 Months 9-35 months 8 852 310 909 354 9-59 months <15 yrs 9-23 months 9 months 5 years 9 months -5 years 9-59 months Classes 1-6 214 128 427 280 974 034 Number of children targeted Number of children reached 216 414 821 708 1 130 370 68 622 214 128 427 280 739 417 Coverage 79 % 96.41 % 124.3 % 100 % 100 % 100 % 75.9 %
DPR Korea India
2001 Indonesia 1997 2000
1 402 621 2 738 580 6 665 950
929 125 2 696 506 6 341 407
66.24 % 98.5 % 95. 1%
2000
6 -59 months
11 42 183
948 012
89.5 %
2001 2002 1997 2001 1995 2002 1997
Maldives Myanmar
9 months – 5 years 6 -59 months 5-14 Years 9 months 3 years 9 months – 5 years 9 months – 5 years
166 087 2 667 343 700
155 101 2 031 029 31 112 450 236 352 1 577 169 1 063 641
93.39 % 76.1% 94 % 64.29 % 90.7 % 88% 90.4 %
1 792 980
Nepal Thailand
1995 2000
Various group from 6 mon. to 18 years
18 985
17 993 18 788
98.96 %
*Source: EPI/TCG reports, WHO
Page 22
Measles Mortality Reduction
Table 6: Estimated vaccine and injection safety equipment requirement for supplemental immunization activities. 2003-2005 Country Banglades h India Indonesia Maldives Myanmar Year for SIA 2005 2005 2004 2005 2002 2003 2004 Nepal Sri Lanka TimorLeste Total 2004 2003 2004 2004 Target age group 9m-5Y 9m-5Y 9m-15Y 9m-15Y 9m-5Y 9m-5Y 9m-5Y 9m-15Y 10-14 Y 16-20 Y 9-15 Y Target population 174 99 169 79 821 150 65 854 626 143 878 1 622 029 1 720 995 2 074 854 10 195 250 2 057 000 1 870 000 254 910 183 113 861 Type of SIA Nationwide five states Nationwide Nationwide 1/3 of country 1/3 of country 1/3 of country Nationwide Nationwide Nationwide Nationwide Vaccine doses 21 873 961 99 776 438 82 318 283 179 848 2 027 536 2 151 244 2 593 568 12 744 063 2 571 250 2 337 500 318 638 228 892 327 AD syringes 19 249 086 87 803 265 72 440 089 158 266 1 784 232 1 893 095 2 282 339 11 214 755 2 262 700 2 057 000 280 401 201 425 248 Reconstitution syringes 2 187 396 9 977 644 8 231 828 17 985 202 754 215 124 259 357 1 274 406 257 125 233 750 31 864 22 889 232 Safety boxes 214 365 977 809 806 719 1 763 19 870 21 082 25 417 124 892 25 198 22 908 3 123 2 243 145
Table 7: Estimated total financial resources required to achieve measles control goals, 2003-2005 Activity Vaccine and injection equipment cost for supplemental immunization Operational cost of supplemental immunization Measles surveillance and laboratory Subtotal for country level activities Operational cost for regional coordination Operational cost laboratory network Total for regional 2003 447 459 326,739 420 700 1 192 898 180 000 120 000 1 492 898 2004 18 692 270 41 119 959 2 198 000 69 500 326 315 000 330 000 70 145 326 2005 26 256 399 59 383 362 2 198 000 86 417 082 390 000 330 000 87 137 082 Total USD 45 396 128 100 830 060 4 816 700 157 112 306 885 000 780 000 158 777 306
Page 23
Regional Strategic Plan 2003-2005
Table 8: Estimated resources requirement for country level measles control activities Activity Vaccine and Injection equipment Year 2003 2004 2005 Sub-total Operational cost of supplemental immunization 2003 2004 2005 Sub-total Measles surveillance and laboratory 2003 2004 2005 Sub-total Sub total 2003 2004 2005 Total 10,499,501 10,499,501 190,000 260,000 260,000 710,000 190,000 260,000 15,309,285 15,759,285 1,380,000 70,026,189 71,406,189 1,380,000 1,380,000 2,760,000 47,892,690 47,892,690 39,512,776 164,000 280,000 280,000 724,000 164,000 56,914,979 280,000 57,358,979 86,327 37,408 123,735 39,512,776 86,327 86,327 650,000 31,200 82,000 82,000 195,200 776,659 971,462 82,000 1,832,121 6,117,150 35,500 176,000 176,000 387,500 35,500 9,086,776 176,000 9,298,276 26,739 561,559 486,200 1,074,498 239,223 20,000 259,223 20,000 20,000 40,000 53,478 152,946 4,549,784 4,549,784 20,753,499 20,753,499 17,122,203 17,122,203 37,408 37,408 986,921 300,000 350,000 6,117,150 2,793,626 1,021,020 26,739 26,739 152,946 66,277 Bangladesh India Indonesia Maldives Myanmar * 447,459 539,462 2,793,626 Nepal Sri Lanka 534,820 486,200 66,277 TimorLeste Subtotal 982,279 21,007,768 25,340,691 47,330,738 326,739 46,159,611 58,478,518 104,964,868 420,700 2,198,000 2,198,000 4,816,700 1,192,898 69,500,326 86,417,082 157,112,306
Assumptions for calculating the financial resources: Ø Measles vaccine and safety injection equipment cost in US $ for 2002 for: Ø Cost of measles vaccine is US $ 0.26 per child including the cost of auto disable syringes and the fraction of the cost of the safety box Operational cost for supplementary vaccination, according to global estimations(planning, supervision, transport, per diem, social mobilization and training):US $0.6 per targeted child
Operational cost for disease surveillance and laboratory: Included for countries already assisted by SMOs for AFP surveillance. Measles surveillance for 2003 is based on actual estimates of the countries. For 2004 and 2005, it is assumed that additional amount of 20% of the 2003 AFP surveillance budget would be required for measles surveillance. Countries which are not assisted by SMO network will be technically assisted through the budget allocated for regional coordination and regional laboratory network, in susceptibility analysis for measles, evaluating campaigns and in providing technical support and essential material for laboratories. *Already funds have been identified for campaigns in 2003 (Myanmar through CIDA and Sri Lanka through CDC). All other activities are subject to availability of funds and bundled vaccines. Currently measles mortality is not a problem in Bhutan, DPR Korea and Thailand. So far these countries have not prepared a plan of action aiming elimination. Technical assistance for these countries to analyze susceptibility for measles and improve surveillance with laboratory confirmation will be provided through resources allocated for regional coordination and regional laboratory network.
Ø
Ø Ø
Page 24